title: Lung cancer screening: did we really need a randomized controlled trial?
abstract: Lung cancer is the leading cause of cancer mortality in the USA. Within the past decade, two large trials (the National Lung Screening Trial Research and the International Early Lung Cancer Action Program) confirmed a significant role for low-dose CT (LDCT) screening in identifying early stages of cancer leading to reduced mortality in high-risk patients. Given the evidence, the US Preventive Services Task Force issued a recommendation in favour of LDCT screening for high-risk individuals. Despite the strong support for LDCT among physicians who treat lung cancer and cumulative data demonstrating a survival benefit for screening and early detection, it took more than a decade for lung cancer screening to be embraced at the policy level. With many lives lost in the interim, did we really need a randomized controlled trial to make this decision?
authors.affiliation: Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Adnan M
authors.initials: AM
authors.lastname: Al-Ayoubi
authors.affiliation: Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA raja.flores@mountsinai.org.
authors.forename: Raja M
authors.initials: RM
authors.lastname: Flores
mesh_terms: D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer / Q000191:economics / Q000401:mortality* / Q000706:statistics & numerical data; D006801:Humans; D008175:Lung Neoplasms / Q000191:economics / Q000401:mortality / Q000517:prevention & control*; D008403:Mass Screening / Q000191:economics / Q000401:mortality / Q000706:statistics & numerical data; D000069342:Medical Overuse; D016032:Randomized Controlled Trials as Topic; D019564:Unnecessary Procedures
keywords: I-ELCAP; Low-dose CT screening; Lung cancer; NLST